Cargando…
The Incidence of Kidney Injury for Patients Treated With a High‐Potency Versus Moderate‐Potency Statin Regimen After an Acute Coronary Syndrome
BACKGROUND: Observational studies have raised concerns that high‐potency statins increase the risk of acute kidney injury. We therefore examined the incidence of kidney injury across 2 randomized trials of statin therapy. METHODS AND RESULTS: PROVE IT‐TIMI 22 enrolled 4162 subjects after an acute co...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309063/ https://www.ncbi.nlm.nih.gov/pubmed/24786143 http://dx.doi.org/10.1161/JAHA.114.000784 |
_version_ | 1782354629369004032 |
---|---|
author | Sarma, Amy Cannon, Christopher P. de Lemos, James Rouleau, Jean L. Lewis, Eldrin F. Guo, Jianping Mega, Jessica L. Sabatine, Marc S. O'Donoghue, Michelle L. |
author_facet | Sarma, Amy Cannon, Christopher P. de Lemos, James Rouleau, Jean L. Lewis, Eldrin F. Guo, Jianping Mega, Jessica L. Sabatine, Marc S. O'Donoghue, Michelle L. |
author_sort | Sarma, Amy |
collection | PubMed |
description | BACKGROUND: Observational studies have raised concerns that high‐potency statins increase the risk of acute kidney injury. We therefore examined the incidence of kidney injury across 2 randomized trials of statin therapy. METHODS AND RESULTS: PROVE IT‐TIMI 22 enrolled 4162 subjects after an acute coronary syndrome (ACS) and randomized them to atorvastatin 80 mg/day versus pravastatin 40 mg/day. A‐to‐Z enrolled 4497 subjects after ACS and randomized them to a high‐potency (simvastatin 40 mg/day×1 months, then simvastatin 80 mg/day) versus a delayed moderate‐potency statin strategy (placebo×4 months, then simvastatin 20 mg/day). Serum creatinine was assessed centrally at serial time points. Adverse events (AEs) relating to kidney injury were identified through database review. Across both trials, mean serum creatinine was similar between treatment arms at baseline and throughout follow‐up. In A‐to‐Z, the incidence of a 1.5‐fold or ≥0.3 mg/dL rise in serum creatinine was 11.4% for subjects randomized to a high‐potency statin regimen versus 12.4% for those on a delayed moderate‐potency regimen (odds ratio [OR], 0.91; 95% confidence interval [CI], 0.76 to 1.10; P=0.33). In PROVE IT‐TIMI 22, the incidence was 9.4% for subjects randomized to atorvastatin 80 mg/day and 10.6% for subjects randomized to pravastatin 40 mg/day (OR, 0.88; 95% CI, 0.71 to 1.09; P=0.25). Consistent results were observed for different kidney injury thresholds and in individuals with diabetes mellitus or with moderate renal dysfunction. The incidence of kidney injury‐related adverse events (AEs) was not statistically different for patients on a high‐potency versus moderate‐potency statin regimen (OR, 1.06; 95% CI, 0.68 to 1.67; P=0.78). CONCLUSIONS: For patients enrolled in 2 large randomized trials of statin therapy after ACS, the use of a high‐potency statin regimen did not increase the risk of kidney injury. |
format | Online Article Text |
id | pubmed-4309063 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-43090632015-01-28 The Incidence of Kidney Injury for Patients Treated With a High‐Potency Versus Moderate‐Potency Statin Regimen After an Acute Coronary Syndrome Sarma, Amy Cannon, Christopher P. de Lemos, James Rouleau, Jean L. Lewis, Eldrin F. Guo, Jianping Mega, Jessica L. Sabatine, Marc S. O'Donoghue, Michelle L. J Am Heart Assoc Original Research BACKGROUND: Observational studies have raised concerns that high‐potency statins increase the risk of acute kidney injury. We therefore examined the incidence of kidney injury across 2 randomized trials of statin therapy. METHODS AND RESULTS: PROVE IT‐TIMI 22 enrolled 4162 subjects after an acute coronary syndrome (ACS) and randomized them to atorvastatin 80 mg/day versus pravastatin 40 mg/day. A‐to‐Z enrolled 4497 subjects after ACS and randomized them to a high‐potency (simvastatin 40 mg/day×1 months, then simvastatin 80 mg/day) versus a delayed moderate‐potency statin strategy (placebo×4 months, then simvastatin 20 mg/day). Serum creatinine was assessed centrally at serial time points. Adverse events (AEs) relating to kidney injury were identified through database review. Across both trials, mean serum creatinine was similar between treatment arms at baseline and throughout follow‐up. In A‐to‐Z, the incidence of a 1.5‐fold or ≥0.3 mg/dL rise in serum creatinine was 11.4% for subjects randomized to a high‐potency statin regimen versus 12.4% for those on a delayed moderate‐potency regimen (odds ratio [OR], 0.91; 95% confidence interval [CI], 0.76 to 1.10; P=0.33). In PROVE IT‐TIMI 22, the incidence was 9.4% for subjects randomized to atorvastatin 80 mg/day and 10.6% for subjects randomized to pravastatin 40 mg/day (OR, 0.88; 95% CI, 0.71 to 1.09; P=0.25). Consistent results were observed for different kidney injury thresholds and in individuals with diabetes mellitus or with moderate renal dysfunction. The incidence of kidney injury‐related adverse events (AEs) was not statistically different for patients on a high‐potency versus moderate‐potency statin regimen (OR, 1.06; 95% CI, 0.68 to 1.67; P=0.78). CONCLUSIONS: For patients enrolled in 2 large randomized trials of statin therapy after ACS, the use of a high‐potency statin regimen did not increase the risk of kidney injury. Blackwell Publishing Ltd 2014-05-01 /pmc/articles/PMC4309063/ /pubmed/24786143 http://dx.doi.org/10.1161/JAHA.114.000784 Text en © 2014 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/3.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Research Sarma, Amy Cannon, Christopher P. de Lemos, James Rouleau, Jean L. Lewis, Eldrin F. Guo, Jianping Mega, Jessica L. Sabatine, Marc S. O'Donoghue, Michelle L. The Incidence of Kidney Injury for Patients Treated With a High‐Potency Versus Moderate‐Potency Statin Regimen After an Acute Coronary Syndrome |
title | The Incidence of Kidney Injury for Patients Treated With a High‐Potency Versus Moderate‐Potency Statin Regimen After an Acute Coronary Syndrome |
title_full | The Incidence of Kidney Injury for Patients Treated With a High‐Potency Versus Moderate‐Potency Statin Regimen After an Acute Coronary Syndrome |
title_fullStr | The Incidence of Kidney Injury for Patients Treated With a High‐Potency Versus Moderate‐Potency Statin Regimen After an Acute Coronary Syndrome |
title_full_unstemmed | The Incidence of Kidney Injury for Patients Treated With a High‐Potency Versus Moderate‐Potency Statin Regimen After an Acute Coronary Syndrome |
title_short | The Incidence of Kidney Injury for Patients Treated With a High‐Potency Versus Moderate‐Potency Statin Regimen After an Acute Coronary Syndrome |
title_sort | incidence of kidney injury for patients treated with a high‐potency versus moderate‐potency statin regimen after an acute coronary syndrome |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309063/ https://www.ncbi.nlm.nih.gov/pubmed/24786143 http://dx.doi.org/10.1161/JAHA.114.000784 |
work_keys_str_mv | AT sarmaamy theincidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome AT cannonchristopherp theincidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome AT delemosjames theincidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome AT rouleaujeanl theincidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome AT lewiseldrinf theincidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome AT guojianping theincidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome AT megajessical theincidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome AT sabatinemarcs theincidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome AT odonoghuemichellel theincidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome AT sarmaamy incidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome AT cannonchristopherp incidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome AT delemosjames incidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome AT rouleaujeanl incidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome AT lewiseldrinf incidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome AT guojianping incidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome AT megajessical incidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome AT sabatinemarcs incidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome AT odonoghuemichellel incidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome |